Tibotec Pharmaceuticals hopeful for TMC278 after positive Phase III results

摘要

The results from two large-scale clinical trials into the efficacy of TMC278 (provisionally called Rilpivirine; Tibotec Pharmaceuticals, Cork, Ireland), a novel investigational HIV drug, were recently released, showing noninferiority versus efavirenz in the proportion of patients achieving an undetectable viral load (less than 50 copies/ml) at week 48. This will be the third anti-HIV drug to be developed by speciality pharmaceutical company Tibotec, a subsidiary of Johnson and Johnson. Tibotec hope that these Phase III results will form part of the evidence supporting their recent application to market TMC278 in the USA.